Research Data from University of Porto Update Understanding of Secondary Hyperparathyroidism (Etelcalcetide Controls Secondary Hyperparathyroidism and Raises Sclerostin Levels In Hemodialysis Patients Previously Uncontrolled With Cinacalcet).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      PORTO (Portugal)
    • Abstract:
      Keywords: Porto; Portugal; Europe; Calcium-Sensing Receptor Agonist; Cinacalcet; Dialysis; Drugs and Therapies; Endocrine System Diseases and Conditions; Health and Medicine; Hemodialysis; Hyperparathyroidism; Parathyroid Diseases and Conditions; Secondary Hyperparathyroidism EN Porto Portugal Europe Calcium-Sensing Receptor Agonist Cinacalcet Dialysis Drugs and Therapies Endocrine System Diseases and Conditions Health and Medicine Hemodialysis Hyperparathyroidism Parathyroid Diseases and Conditions Secondary Hyperparathyroidism 2459 2459 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Parathyroid Diseases and Conditions - Secondary Hyperparathyroidism. Porto, Portugal, Europe, Calcium-Sensing Receptor Agonist, Cinacalcet, Dialysis, Drugs and Therapies, Endocrine System Diseases and Conditions, Health and Medicine, Hemodialysis, Hyperparathyroidism, Parathyroid Diseases and Conditions, Secondary Hyperparathyroidism. [Extracted from the article]
    • Abstract:
      Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)